ALNEV — Neovacs SA Balance Sheet
0.000.00%
- €0.01m
- -€0.03m
- €0.16m
Annual balance sheet for Neovacs SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 33.1 | 6.76 | 0.887 | 0.435 | 0.572 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.6 | 1.81 | 2.78 | 1.95 | 1.95 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 34.8 | 9.07 | 3.81 | 2.48 | 2.64 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.506 | 0.511 | 0.527 | 0.415 | 0.236 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 48.6 | 55.3 | 52.6 | 22.1 | 22.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.65 | 5.12 | 3.71 | 3.84 | 3.15 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4.65 | 5.13 | 3.72 | 4.01 | 4.11 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 43.9 | 50.2 | 48.8 | 18.1 | 18.1 |
| Total Liabilities & Shareholders' Equity | 48.6 | 55.3 | 52.6 | 22.1 | 22.2 |
| Total Common Shares Outstanding |